There is evidence to suggest that dietary supplements such as omega-3 containing fish-oil, specifically the polyunsaturated fatty acid 20:5n3 component (also Belnacasan datasheet commonly known as eicosapentaenoic acid or EPA), may be efficient at reducing the pro-inflammatory cytokines associated with inflammation [18, 19]. Magee et al. [18] demonstrated in vitro that EPA inhibited the effects of TNF-α by reducing its apoptotic effects and enabling myogenesis, thus allowing optimal skeletal muscle cell differentiation from myoblasts into myotubes, a process which is key in the regeneration Selumetinib of muscle following damage. Complimentary evidence was provided in vivo by Matsuyama
et al. [19] who worked with patients suffering
from chronic obstructive pulmonary disease (COPD). COPD is characterised by chronic inflammation and pain in the throat and chest when breathing. Matsuyama et al. [19] treated patients for 24 months with EPA supplementation. With treatment, participants exhibited lower TNF-α levels and reported a reduction pain in comparison with baseline values. The findings from these two studies suggest a link between elevated levels of pro-inflammatory cytokines and pain [6] and also that EPA may be beneficial in reducing the symptoms of DOMS and the level of inflammation associated Adriamycin chemical structure with it. In this potential therapeutic context, several studies have already queried whether Cyclin-dependent kinase 3 omega-3/EPA doses between 300 mg/day to 2224 mg/day can affect the acute inflammation response and symptoms associated with DOMS after a single bout of exercise [3, 20, 21]. Lenn et al. [3], using 1800 mg/day of omega-3, reported that EPA had no effect on range of motion, pain, IL-6, TNF-α and creatine kinase levels. However, Phillips
et al. [20] (using a daily cocktail of 300 mg of tocopherols plus 800 mg of docosahexaenoate plus 300 mg of flavonoids) and Bloomer et al. [21] (using 2224 mg/day of EPA) both reported a reduction in IL-6, CRP and TNF-α respectively, following a single bout of exercise. These studies in conjunction with the in vivo and in vitro work mentioned earlier [18, 19] exemplify the confusion as to whether EPA may be beneficial in reducing pro-inflammatory cytokines linked with the inflammatory response and the symptoms associated with DOMS. To date the impact of fish oils on the acute and chronic response to a single bout of exercise remains unclear. Moreover, the conventional dose of 1000-2000 mg per day (of total fish oil or 180-360 of EPA) has mainly been far exceeded in the research to date. Aims and Objectives The aims of the present study were therefore to investigate the effects of a dose of EPA supplementation just above standard recommendations, on basal inflammation, as well on both the acute and the chronic resistance exercise responses.